drugset / Trial / NCT00760461

Domperidone in Refractory Gastroparesis

NCT00760461

Phase 2 Terminated 44 enrolled Yale University
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.

Timeline

Start
2008-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Domperidone Unknown 10 mg Oral
Subject Domperidone Unknown 20 mg Oral
Subject Domperidone Unknown 30 mg Oral

Indications